A prospective study to evaluate the effect of the Molecular Adsorbent Recirculating System (MARS®) for patients with acute liver failure: a randomized controlled study

Gambro Korea Ltd (Korea, South)0 sites50 target enrollmentJanuary 8, 2014

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Acute liver failureAcute on chronic liver failure due to hepatitis B
Sponsor: Gambro Korea Ltd (Korea, South)
Enrollment: 50
Status: Completed
Last Updated: 11 years ago

No summary available.

Registry

who.int

Start Date

January 8, 2014

End Date

TBD

Last Updated

11 years ago

Study Type

Interventional

Sex

All

Sponsor

Gambro Korea Ltd (Korea, South)

•1\. Acute liver failure patient in accordance with American Association for the Study of Liver Diseases (AASLD) guideline
•2\. Age between 20 and 70
•3\. Patient with a sign of hepatic encephalopathy
•4\. If a patient is able to make decisions on his/her own, a subject?s own consent and signature is required. However, if a patient is unable to make decisions on his/her own due to hepatic coma, a consent and signature by a legal representative is required.
•5\. All of the above
•6\. Or acute\-on\-chronic liver failure (AoCLF) with hepatitis B including No. 2, 3 and 4 above

•1\. Acute liver failure due to acetaminophen
•2\. Acute hepatitis A
•3\. Patient with a sign of hepatic encephalopathy due to alcoholic hepatitis
•4\. Patient with anamnesis of chronic liver disease (except hepatitis B)
•5\. Among autoimmune disease patients with abrupt recurrence, those who display varix and nodularity on CT or duodenoscopy
•6\. Patient with anamnesis of hepatocirrhosis (except hepatitis B)
•7\. Septic shock
•8\. Patient with irreciprocal multiorgan failure
•9\. Abrupt bleeding
•10\. Pregnant or lactating women